[1]
|
Chen, J.J., Ma, X.J., Liu, F., et al. (2016) Epidemiologic Features of Kawasaki Disease in Shanghai from 2008 through 2012. The Pediatric Infectious Disease Journal, 35, 7-12. https://doi.org/10.1097/INF.0000000000000914
|
[2]
|
Singh, S., Vignesh, P. and Burgner, D. (2015) The Epidemiology of Kawasaki Disease: A Global Update. Archives of Disease in Childhood, 100, 1084-1088. https://doi.org/10.1136/archdischild-2014-307536
|
[3]
|
Holman, R.C., Christensen, K.Y., Belay, E.D., et al. (2010) Racial/Ethnic Differences in the Incidence of Kawasaki Syndrome among Children in Hawaii. Hawaii Medical Journal, 69, 194-197.
|
[4]
|
McCrindle, B.W., Rowley, A.H., Newburger, J.W., et al. (2017) Diagnosis, Treatment and Long-Term Management of Kawasaki Disease. A Scientific Statement for Health Professionals from the American Heart Association. Circulation Journal, 135, e927-e999.
|
[5]
|
Singh, S., Sharma, A. and Jiao, F.Y. (2016) Kawasaki Disease: Issues in Diagnosis and Treatment: A Developing Country Perspective. Indian Journal of Pediatrics, 83, 140-145. https://doi.org/10.1007/s12098-015-1890-4
|
[6]
|
Michihata, N., Matsui, H., Fushimi, K., et al. (2015) Guideline-Concordant Treatment of Kawasaki Disease with Immunoglobulin and Aspirin and the Incidence of Coronary Artery Aneurysm. Clinical Pediatrics, 54, 1076-1080.
https://doi.org/10.1177/0009922814566932
|
[7]
|
Terai, M. and Shulman, S.T. (1997) Prevalence of Coronary Artery Abnormalities in Kawasaki Disease Is Highly Dependent on Gamma Globulin Dose But Independent of Salicylate Dose. Journal of Pediatrics, 131, 888-893.
https://doi.org/10.1016/S0022-3476(97)70038-6
|
[8]
|
Dhanrajani, A. and Yeung, R.S.M. (2017) Revisiting the Role of Steroids and Aspirin in the Management of Acute Kawasaki Disease. Current Opinion in Rheumatology, 29, 547⁃552. https://doi.org/10.1097/BOR.0000000000000425
|
[9]
|
Gurbel, P.A., Bliden, K.P., DiChiara, J., et al. (2007) Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results from the Aspirin-Induced Platelet Effect (ASPECT) Study. Circulation, 115, 3156-3164.
https://doi.org/10.1161/CIRCULATIONAHA.106.675587
|
[10]
|
Dallaire, F., Fortier-Morissette, Z., Blais, S., et al. (2017) Aspirin Dose and Prevention of Coronary Abnormalities in Kawasaki Disease. Pediatrics, 139, e20170098. https://doi.org/10.1542/peds.2017-0098
|
[11]
|
Durongpisitkul, K., Gururaj, V.J., Park, J.M., et al. (1995) The Prevention of Coronary Artery Aneurysm in Kawasaki Disease: A Meta-Analysis on the Efficacy of Aspirin and Immunoglobulin Treatment. Pediatrics, 96, 1057-1061.
|
[12]
|
Furusho, K., Kamiya, T., Nakano, H., et al. (1992) Intravenous γ-Globulin for Kawasaki Disease. Acta Paediatrica Japonica, Overseas Edition, 33, 799-804. https://doi.org/10.1111/j.1442-200X.1991.tb02611.x
|
[13]
|
Kato, H., Koike, S. and Yokoyama, T. (1979) Kawasaki Disease: Effect of Treatment on Coronary Artery Involvement. Pediatrics, 63, 175-179.
|
[14]
|
JCS Joint Working Group (2010) Guidelines for Diagnosis and Management of Cardiovascular Sequelae in Kawasaki Disease (JCS 2008)-Digest Version. Circulation Journal, 74, 1989-2020. https://doi.org/10.1253/circj.CJ-10-74-0903
|
[15]
|
张胜, 梁雪. 川崎病治疗研究进展[J]. 国际儿科学杂志, 2018, 45(8): 584-588.
|
[16]
|
Eleftheriou, D., Levin, A.M., Shingadia, D., et al. (1988) Management of Kawasaki Disease. The Journal of Pediatrics, 113, 1116-1117. https://doi.org/10.1016/S0022-3476(88)80596-1
|
[17]
|
Sundel, R.P., Burns, J.C., Baker, A., et al. (1993) Gamma Globulin Re-Treatment in Kawasaki Disease. Journal of Pediatrics, 123, 657-659. https://doi.org/10.1016/S0022-3476(05)80972-2
|
[18]
|
Simic, M. (1999) Corticosteroids in the Treatment of the Acute Phase of Kawasaki Disease. Journal of Pediatrics, 135, 465-469. https://doi.org/10.1016/S0022-3476(99)70169-1
|
[19]
|
Sundel, R.P., Baker, A.L., Fulton, D.R., et al. (2003) Corticosteroids in the Initial Treatment of Kawasaki Disease: Report of a Randomized Trial. The Journal of Pediatrics, 142, 611-616. https://doi.org/10.1067/mpd.2003.191
|
[20]
|
Inoue, Y., Okada, Y., Shinohara, M., et al. (2006) A Multicenter Prospective Randomized Trial of Corticosteroids in Primary Therapy for Kawasaki Disease: Clinical Course and Coronary Artery Outcome. Journal of Pediatrics, 149, 336-341. https://doi.org/10.1016/j.jpeds.2006.05.025
|
[21]
|
Kobayashi, T., Saji, T., Otani, T., et al. (2012) Efficacy of Immunoglobulin plus Prednisolone for Prevention of Coronary Artery Abnormalities in Severe Kawasaki Disease (RAISE Study): A Randomized, Open-Label, Blinded-End- points Trial. The Lancet, 379, 1613-1620. https://doi.org/10.1016/S0140-6736(11)61930-2
|
[22]
|
Chen, S., Dong, Y. and Marcio, G.K. (2016) Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention: A Systematic Review and Meta-Analysis. JAMA Pediatrics, 170, 1156-1163.
https://doi.org/10.1001/jamapediatrics.2016.2055
|
[23]
|
Wardle, A.J., Kiddy, H.C., Seager, M.J., et al. (2014) Corticosteroids for the Treatment of Kawasaki Disease in Children. Cochrane Database of Systematic Reviews, No. 8, CD011188. https://doi.org/10.1002/14651858.CD011188
|
[24]
|
Chen, S., Dong, Y., Yin, Y., et al. (2013) Intravenous Immunoglobulin plus Corticosteroid to Prevent Coronary Artery Abnormalities in Kawasaki Disease: A Meta-Analysis. Heart, 99, 76-82. https://doi.org/10.1136/heartjnl-2012-302126
|